Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080649 | 0.89 | TRPM8 (0.46) | TRPM8HSD17B2FFAR1MAPTPKM | |
| SCHEMBL1095799 | 0.82 | MAPT (0.38) | MAPTPKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1105934 | 0.81 | CCR5 (0.41) | TRPM8HSD17B2FFAR1 | |
| SCHEMBL1105754 | 0.78 | ALOX5 (0.41) | HSD17B2MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL1097046 | 0.76 | CCR5 (0.37) | SLC6A2SLC6A4SLC6A3REN | |
| SCHEMBL4578555 | 0.76 | USP30 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1096141 | 0.76 | TRPM8 (0.43) | TRPM8HSD17B2FFAR1MAPTPKM | |
| SCHEMBL1096458 | 0.75 | CXCR3 (0.37) | TRPM8HSD17B2FFAR1MAPT | |
| SCHEMBL1096262 | 0.75 | REN (0.37) | MAPTPKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16274994 | 0.73 | REN (0.40) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | TRPM8 145/4885HSD17B2 1097/4885FFAR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.